Not currently recruiting at University of California Health
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedestimated completion
- Principal Investigator
- by Sara Hurvitz (ucla)Victor Chiu (ucla)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientists at University of California Health
- Sara Hurvitz (ucla)
Professor, Medicine. Authored (or co-authored) 145 research publications - Victor Chiu (ucla)
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMONARCH)
- ID
- NCT05169567
- Phase
- Phase 3 Research Study
- Study Type
- Interventional
- Participants
- Expecting 350 study participants
- Last Updated